anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

158,281-158,340 of 319,975

filter-aware
22
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
23
The slide categorizes revenue sources into three segments: Current Proprietary Commercial Products, Under FDA Review, and Royalty Stream.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
24
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
25
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
26
Uses a process-like visual flow to connect strategic priorities to business outcomes.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
27
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
28
The slide uses a two-column list structure to categorize launch activities.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
29
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
30
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
31
The bridge chart illustrates the path from 7% to ~25% margin using three levers: commercial operating leverage, R&D prioritization, and G&A/manufacturing efficiency.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
32
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
33
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
34
The slide highlights board independence, diversity, and tenure metrics alongside governance updates.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
35
The slide uses symbols (star and circle) to denote new directors and retiring directors, explained in the top right legend.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
36
The slide uses a 2x2-style grid layout to contrast commercial products with development pipeline candidates.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
37
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
38
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
39
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
40
The diagram uses a central hexagon surrounded by six peripheral hexagons, representing a multi-factor evaluation framework.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
41
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
42
The table serves as evidence of the 'quicker kills' strategy mentioned in the bullet points.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
43
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
44
The slide uses a hub-and-spoke style diagram to connect strategic inputs to a central outcome.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
45
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
46
The diagram uses a hexagonal cluster to represent the central 'High-Value Development Candidate' surrounded by key strategic inputs.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
47
The slide uses a side-by-side comparison structure to highlight technical capabilities.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
48
The slide highlights a tech stack including KNIME, Docker, AWS, and RDKit integrated into a proprietary platform.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
49
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
50
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
51
The slide uses a structured table to categorize drug development candidates by their biological mechanism.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
52
The slide uses molecular modeling imagery to illustrate different engineering approaches (Mutation, Fusion, ScFv Bispecific, Fusionbody, IgG Bispecific).Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
53
The slide uses a combination of biological diagrams and a structured comparison matrix to explain the therapeutic rationale for each cytokine.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
54
The chart uses horizontal bars to represent the progress of different R&D programs across clinical phases.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
55
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
56
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
57
The diagram illustrates a transition from legacy treatments to engineered specificity.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
58
The slide uses a visual metaphor of steric occlusion to explain the mechanism of action.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
59
Uses a causal chain/additive framework to build the argument.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
60
Uses a Venn-like diagram to contrast existing therapy strategies with new development strategies.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
61
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
62
Data cutoff March 1, 2021. PR=partial response, RP2D=Recommended Phase 2 Dose.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
63
Data as of December 2020.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
64
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
65
The slide uses a two-column layout to contrast general melanoma burden with the specific, more severe challenges of mucosal melanoma.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
66
The slide outlines the patient population (refractory to prior therapies) and the statistical design (Simon Two-Stage) used to determine cohort expansion.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
67
The chart is a swimmer plot (a type of timeline/bar chart used in oncology clinical trials).Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
68
The slide uses a structured clinical case format to demonstrate drug efficacy.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
69
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
70
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
71
The slide uses a two-column layout to contrast disease burden with treatment limitations, supported by extensive clinical citations.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
72
Swimmer plot showing patient outcomes over time.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
73
The table tracks individual patient outcomes (OC1-OC5) in a platinum-resistant ovarian cancer cohort.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
74
Patient profile and clinical efficacy data for a specific case study.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
75
The slide highlights a specific focus on ARTISTRY-2 (subcutaneous) with an orange border.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
76
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
77
RP2D = Recommended Phase 2 Dose; SC = Subcutaneous; q7d = every 7 days.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
78
The slide uses a three-column layout to summarize clinical safety data.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
79
The slide highlights the efficacy of the SC 3 mg q7d regimen in expanding effector cells compared to IV administration.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
80
The slide outlines the transition from dose escalation cohorts (q7d and q21d) to a specific Phase 2 expansion cohort at 3.0 mg q7d.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
81
Patient profile includes diagnosis, prior treatment history, current study activity, and clinical outcomes.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit